SEC comment letter
Filing comparison
SEC staff questioned Cryoport, Inc.'s accounting for MD&A
Letter dated 2025-07-31; published on EDGAR 2026-01-13 — the SEC releases comment letters only after the review closes.
We note within your earnings release on Form 8-K as well as the earnings call presentation that you quantify the amount of revenue earned related to Commercial Cell & Gene Therapy. In fact, it is the first bullet in your earnings release for the first quarter of 2025 and you have emphasized those results in that period's earnings call. Therefore, please tell us and quantify in future filings the Commercial Cell &…
Evidence
- Direction
- staff to company
- Letter dated
- 2025-07-31
- Published on edgar
- 2026-01-13
- Reviewing
- Cryoport, Inc. Form 10-K fo the fiscal year ended December 31, 2024 File No. 001-34632 Dear Robert S. Stefanovich: We have limited our review of your filing to
- Source
- SEC staff comment letter (UPLOAD)
- Topics
- MD&A
- Why
- SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.